Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 5:18 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 307 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: thymoglobulin Clear all

Conditions: Leukemia
Interventions: Busulfan, Fludarabine, Thymoglobulin, Total Body Irradiation; Drug · Radiation
Lead sponsor: Ann & Robert H Lurie Children's Hospital of Chicago; Other
Eligibility: Up to 21 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Kidney Transplantation
Interventions: Thymoglobulin; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: anti-thymocyte globulin, melphalan; Biological · Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 120 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Sickle Cell Disease
Interventions: Bone Marrow Transplant (BMT), Hydroxyurea, Thiotepa, Fludarabine monophosphate, Cyclophosphamide, Rabbit Anti-thymocyte Globulin, Total Body Irradiation; Procedure · Drug · Other + 1 more
Lead sponsor: Emory University; Other
Eligibility: 15 Years to 40 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: AML, Childhood, Aml, Acute Myeloid Leukemia, Pediatric, Acute Myeloid Leukemia
Interventions: Rabbit Anti thymocyte globulin, Busulfan, Fludarabine, Thiotepa, Melphalan, TCR alpha beta / CD19+ depleted haploidentical hematopoietic progenitor cell graft, memory-like natural killer cells, IL-2, Plerixafor, Granulocyte Colony-Stimulating Factor, CliniMACS; Drug · Biological · Device
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Leukemia, Acute, Chronic Myelogenous Leukemia (CML), Myelodysplastic Syndrome (MDS), Non-Hodgkin Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Acute Myelogenous Leukemia (AML), Acute Lymphoblastic Leukemia (ALL)
Interventions: Regulatory T-cells, Conventional T-cells, Melphalan, Thiotepa, Fludarabine, Anti-thymocyte globulin, rabbit, CliniMACS CD34 Reagent System; Drug · Device
Lead sponsor: Everett Meyer; Other
Eligibility: Up to 60 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Stanford, California

Conditions: Systemic Sclerosis
Interventions: RIC alloBMT w PTCy in refractory SSc; Biological
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 65 Years
Enrollment: 1 participant
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Adult Acute Myeloid Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Interventions: filgrastim, Anti-Thymocyte Globulin, busulfan, fludarabine phosphate, methotrexate, tacrolimus, Allogeneic Hematopoietic Stem Cell Transplantation; Biological · Drug · Procedure
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 60 Years to 74 Years
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2016
U.S. locations: 21
States / cities: San Francisco, California • Lewes, Delaware • Newark, Delaware + 13 more

Conditions: Absolute Uterine Infertility
Interventions: Uterine Transplant; Procedure
Lead sponsor: Baylor Research Institute; Other
Eligibility: 20 Years to 35 Years · Female only
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2026
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Sickle Cell Disease, Sickle Cell Disorder, Hemoglobinopathies, Thalassemia, Anemia, Sickle Cell
Interventions: Cyclophosphamide, Pentostatin, Rabbit anti-thymocyte globulin, Tacrolimus, Mycophenolate mofetil, CD4+ T-cell-depleted Haploidentical Hematopoietic Transplant; Drug · Biological
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years to 45 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Duarte, California

Conditions: Kidney Diseases
Interventions: Sirolimus; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 80 Years
Enrollment: 177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Myelodysplastic Syndrome, Leukemia
Interventions: Thymoglobulin, Busulfan, Fludarabine, Alloreactive NK Infusion, G-CSF, Tacrolimus, Methotrexate, Interleukin-2; Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Up to 70 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions: Decitabine plus Fludarabine and Busulfan; Drug
Lead sponsor: Hackensack Meridian Health; Other
Eligibility: 45 Years to 80 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Hackensack, New Jersey

Conditions: Lung Transplant
Interventions: thymoglobulin (intraoperative), thymoglobulin (postoperative); Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Fanconi Anemia
Interventions: JSP191, CliniMACS Prodigy System, Depleted Stem Cell Transplant, Rabbit Anti-Thymoglobulin (rATG), Cyclophosphamide, Fludarabine, Rituximab; Drug · Device · Biological
Lead sponsor: Porteus, Matthew, MD; Other
Eligibility: 2 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: Stanford, California

Conditions: Autoimmune Disease, Neurologic Autoimmune Disease, Autologous Transplant Autoimmune, Multiple Sclerosis Transplant, MS Stem Cell Transplant, Multiple Sclerosis Stem Cell Transplant, Stiff Person Syndrome, HCT for Neurologic Autoimmune Disorders, CIDP Transplant, Myasthenia Gravis Transplant, Autoimmune Nervous System Disorder, Central Nervous System Vasculitis, Cerebellar Degeneration, Chronic Inflammatory Demyelinating Polyneuropathy, Lambert Eaton Myasthenic Syndrome, Myasthenia Gravis, Neuromyelitis Optica, Opsoclonus Myoclonus Syndrome, Rasmussen Subacute Encephalitis
Interventions: Anti-Thymocyte Globulin, Autologous Hematopoietic Stem Cell Transplantation, Carmustine, Cytarabine, Etoposide, Laboratory Biomarker Analysis, Melphalan, Peripheral Blood Stem Cell Transplantation, Prednisone, Syngeneic Bone Marrow Transplantation; Biological · Procedure · Drug + 1 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: Up to 71 Years
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2030
U.S. locations: 3
States / cities: Denver, Colorado • Seattle, Washington

Conditions: Sickle Cell Disease
Interventions: Fludarabine monophosphate, Rituximab, Busulfan, ATG, Cyclophosphamide, Mycophenolate mofetil, Tacrolimus; Drug
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: Up to 21 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Kidney Failure, Chronic
Interventions: Thymoglobulin, Daclizumab, Plasmapheresis, Mycophenolate mofetil, Tacrolimus, Dexamethasone, Prednisone, Cytogam; Drug · Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Leukemia
Interventions: Busulfan, Fludarabine, Clofarabine, Total Body Irradiation (TBI), Thymoglobulin, Stem Cell Infusion, Cyclophosphamide, Tacrolimus, Mycophenolate mofetil, Decitabine, Cytarabine, Idarubicin; Drug · Radiation · Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 60 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Myelodysplastic Syndrome, Leukemia
Interventions: Cord Blood Infusion, Busulfan, Fludarabine, Rituximab, ATG, Cyclophosphamide, Clofarabine, Total Body Irradiation (TBI), Melphalan, Tacrolimus, Mycophenolate Mofetil, G-CSF; Procedure · Drug · Other + 1 more
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 1 Year to 80 Years
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Type 1 Diabetes Mellitus
Interventions: Antithymocyte Globulin (ATG), Teplizumab; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 4 Years to 34 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 6
States / cities: Aurora, Colorado • New Haven, Connecticut • Gainesville, Florida + 3 more

Conditions: Transplants and Implants
Interventions: Prednisone, rabbit antithymocyte globulin, Tacrolimus, Mycophenolate mofetil; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 19 Years to 74 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Kidney Transplantation
Interventions: Allogeneic Bone Marrow, Anti-Thymocyte Globulin (Sangstat) & Sirolimus (Wyeth-Ay; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 12 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Non-Neoplastic Hematologic and Lymphocytic Disorder
Interventions: Allogeneic Bone Marrow Transplantation, Anti-Thymocyte Globulin, Cyclosporine, Fludarabine Phosphate, Laboratory Biomarker Analysis, Methotrexate, Mycophenolate Mofetil, Peripheral Blood Stem Cell Transplantation, Tacrolimus, Total-Body Irradiation, Treosulfan, Umbilical Cord Blood Transplantation; Procedure · Biological · Drug + 2 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: Up to 49 Years
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2020
U.S. locations: 6
States / cities: Aurora, Colorado • Portland, Oregon • Nashville, Tennessee + 2 more

Search by objective public record fields.

Allogeneic Transplantation for Pediatric Leukemias With Unrelated Donors

Single Dose Thymoglobulin for Induction in Adult Renal Allograft Recipients

Anti-thymocyte Globulin and Melphalan in Treating Patients With Relapsed Multiple Myeloma

Transplantation for Patients With Sickle Cell Disease From Mismatched Family Donors of Bone Marrow

Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML

Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells

RIC alloBMT With Post-transplant Cyclophosphamide for Refractory Systemic Sclerosis

Fludarabine and Busulfan Followed by Allogeneic Stem Cell Transplant in Treating Older Patients With Acute Myeloid Leukemia in First Complete Remission

Uterine Transplantation and Pregnancy Induction in Women Affected by Absolute Uterine Infertility

A Blood Stem Cell Transplant for Sickle Cell Disease

Comparison of Sirolimus to Tacrolimus for Long Term Therapy in Kidney Transplant With no Steroids

Alloreactive NK Cells for Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

PRO#0118: Decitabine Plus Mini Flu-Bu

Intraoperative Versus Postoperative Thymoglobulin in Lung Transplantation

Depleted Donor Stem Cell Transplant in Children and Adults With Fanconi Anemia After Being Conditioned With a Regimen Containing Briquilimab

Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases

A Reduced Toxicity Allogeneic Unrelated Donor Stem Cell Transplantation (SCT) for Severe Sickle Cell Disease

Induction Therapy Study in Live Donor Kidney Transplant Recipients With a Positive Crossmatch

Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML)

Cord Blood Expansion on Mesenchymal Stem Cells

Platform Trial to Delay Stage 3 Diabetes: Comparing Teplizumab With ATG

Prednisone Withdrawal Versus Prednisone Maintenance After Kidney Transplant

Evaluating the Use of Thymoglobulin, Sirolimus, and Donor Bone Marrow With Kidney Transplantation Patients

Treosulfan and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Nonmalignant Inherited Disorders